<DOC>
	<DOCNO>NCT00955695</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy brain may effective prevent brain metastasis patient advance non-small cell lung cancer . It yet know whether radiation therapy effective observation patient advance non-small cell lung cancer . PURPOSE : This randomized phase III trial study radiation therapy brain see well work compare observation prevent brain metastasis patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Radiation Therapy Brain Observation Preventing Brain Metastases Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effectiveness prophylactic cranial radiotherapy patient advance non-small cell lung cancer responsive gefitinib erlotinib hydrochloride . Secondary - Determine progression-free survival patient treat regimen . - Determine overall survival patient treat regimen . - Determine safety tolerability regimen patient . - Determine psycho-neurological effect regimen patient . - Determine quality life patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord prior chemotherapy regimen ( first line v second line ) , disease response status ( complete response partial response v stable disease ) . Patients randomize 1 2 treatment group . - Group 1 : Patients undergo prophylactic brain radiotherapy . - Group 2 : Patients undergo observation . Patients complete quality life ( HVLT , K-ADL , EORTC QLQ-C30 , EORTC-BN20 ) questionnaires periodically . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer Stage IIIB IV disease Must ≥ 8 week gefitinib erlotinib hydrochloride therapy At least 12 week complete response partial response since start gefitinib erlotinib hydrochloride Stable disease allow provided 1 follow criterion meet : EGFR mutation ( exon 19 21 ) Having ≥ 2 follow 3 factor : Female Never smoke Histologically confirm adenocarcinoma lung No evidence brain metastasis CT scan MRI within past 4 week PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 150,000/mm^3 Bilirubin &lt; 1.5 mg/dL Serum creatinine &lt; 1.5 time upper limit normal PRIOR CONCURRENT THERAPY : See Disease Characteristics Received 1 2 prior systemic chemotherapy regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>